Compare SU & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SU | ZTS |
|---|---|---|
| Founded | 1917 | 1952 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8B | 53.9B |
| IPO Year | N/A | 2013 |
| Metric | SU | ZTS |
|---|---|---|
| Price | $49.84 | $125.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $56.50 | ★ $174.60 |
| AVG Volume (30 Days) | 4.2M | ★ 4.8M |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.32% | 1.70% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | 3.06 | ★ 5.94 |
| Revenue | ★ $35,463,676,235.00 | $9,397,000,000.00 |
| Revenue This Year | $0.63 | $3.04 |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | ★ $15.87 | $21.00 |
| Revenue Growth | N/A | ★ 2.68 |
| 52 Week Low | $30.79 | $115.25 |
| 52 Week High | $50.24 | $177.40 |
| Indicator | SU | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 76.62 | 49.11 |
| Support Level | $44.56 | $123.32 |
| Resistance Level | $50.12 | $126.50 |
| Average True Range (ATR) | 1.22 | 2.69 |
| MACD | 0.53 | -0.10 |
| Stochastic Oscillator | 94.90 | 21.94 |
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil production, petroleum refining in Canada and the U.S., and the company's Petro-Canada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, and renewable fuels. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power. The company's operating segments include Oil Sands, Exploration & Production, Refining & Marketing (R&M), and Corporate & eliminations. Geographically, the company generates a majority of its revenue from Canada.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.